Nav: Home

Mitochondria targeting anti-tumor compound

June 26, 2017

Autophagy is a natural cellular mechanism that plays an important role in cellular homeostasis by removing or recycling damage cell components. Mitophagy is autophagy that is specific to mitochondria. The mitochondrion is an organelle responsible for several functions including the production of cellular energy and the initiation of cell death. The removal of damaged mitochondria prevents degeneration of healthy cells, and recent research has found that it is a potentially potent treatment for cancer since mitophagy activation in cancer tissue induces cancer cell death.

In a previous study from Kumamoto University in Japan, researchers developed folic acid-conjugated methyl-β-cyclodextrin (FA-M-β-CyD) which targets folate receptor-α (FR-α)-expressing (+) tumor cells via an unknown autophagic mechanism. The researchers theorized that FA-M-β-CyD inhibited mitochondrial activities, and began experimenting with the compound on a HeLa-derived, cervical cancer cell line (KB cells).

The researchers first evaluated FA-M-β-CyD by comparing its effects with that of three other compounds, as well as a control, on spheroids of FR-α (+) KB cells in vitro. They found that FA-M-β-CyD reduced cancer cell viability significantly more than the other compounds due to its FR-α-mediated cytotoxicity.

Next, the researchers determined that FA-M-β-CyD was localized to the FR-α? (+) KB cell mitochondria and that it significantly increased the mitochondrial transmembrane potential compared to the other compounds tested. The transmembrane potential of the mitochondria controls the energy (ATP) production of the cell, and it was further found that ATP production was significantly reduced in FR-α (+) KB cells. However, when FR-α (-) A549 cancer cells were treated with FA-M-β-CyD, ATP production was not affected.

Kumamoto University researchers then focused on the effect that FA-M-β-CyD had on KB cell ROS production since reactive oxygen species (ROS) are frequently generated by the mitochondria. They found that ROS production was significantly increased in FR-α (+) KB cells but was unaffected in FR-α (-) KB cells. Furthermore, through the production of ROS in FR-α (+) KB cells, FA-M-β-CyD also seemed to cause autophagic vacuole creation.

In vivo experiments of FA-M-β-CyD's antitumor effects in KB cells (FR-α (+)) using human xenograft models showed promise. Not only did a single dose of the compound significantly suppress tumor growth, but there also didn't appear to be any significant major side effects as demonstrated by body weight and blood tests. However, further tests at higher doses are required to confirm the safety of the compound, but the researchers are cautiously optimistic.

"One of the problems for antitumor drugs to overcome is the abnormal blood vessel distribution and blood perfusion in tumors. This hinders the ability of the drug to enter cells and do its job," said Professor Arima, one of the project leaders. "However, recent research has found that nanoparticles around 12 nanometers in size can easily enter tumor cells. FA-M-β-CyD was measured at approximately 10 nm which contributes to its anticancer abilities." The compound should target FR-α? (+) cancer cells, such as those found in ovarian, kidney, breast, endometrium, bladder, lung, and pancreas cancers, but the researchers admit that further testing is required before the safety of the compound can be determined definitively. It is hoped, however, that it will be developed into a potent anticancer drug.

This research can be found online at Dove Medical's International Journal of Nanomedicine.
-end-
[Reference]

Kameyama, K.; Motoyama, K.; Tanaka, N.; Yamashita, Y.; Higashi, T. & Arima, H., Induction of mitophagy-mediated antitumor activity with folate-appended methyl-β-cyclodextrin, International Journal of Nanomedicine, Dove Medical Press Ltd., 2017, Volume 12, 3433-3446
DOI: 10.2147/ijn.s133482

Kumamoto University

Related Cancer Articles:

Radiotherapy for invasive breast cancer increases the risk of second primary lung cancer
East Asian female breast cancer patients receiving radiotherapy have a higher risk of developing second primary lung cancer.
Cancer genomics continued: Triple negative breast cancer and cancer immunotherapy
Continuing PLOS Medicine's special issue on cancer genomics, Christos Hatzis of Yale University, New Haven, Conn., USA and colleagues describe a new subtype of triple negative breast cancer that may be more amenable to treatment than other cases of this difficult-to-treat disease.
Metabolite that promotes cancer cell transformation and colorectal cancer spread identified
Osaka University researchers revealed that the metabolite D-2-hydroxyglurate (D-2HG) promotes epithelial-mesenchymal transition of colorectal cancer cells, leading them to develop features of lower adherence to neighboring cells, increased invasiveness, and greater likelihood of metastatic spread.
UH Cancer Center researcher finds new driver of an aggressive form of brain cancer
University of Hawai'i Cancer Center researchers have identified an essential driver of tumor cell invasion in glioblastoma, the most aggressive form of brain cancer that can occur at any age.
UH Cancer Center researchers develop algorithm to find precise cancer treatments
University of Hawai'i Cancer Center researchers developed a computational algorithm to analyze 'Big Data' obtained from tumor samples to better understand and treat cancer.
New analytical technology to quantify anti-cancer drugs inside cancer cells
University of Oklahoma researchers will apply a new analytical technology that could ultimately provide a powerful tool for improved treatment of cancer patients in Oklahoma and beyond.
Radiotherapy for lung cancer patients is linked to increased risk of non-cancer deaths
Researchers have found that treating patients who have early stage non-small cell lung cancer with a type of radiotherapy called stereotactic body radiation therapy is associated with a small but increased risk of death from causes other than cancer.
Cancer expert says public health and prevention measures are key to defeating cancer
Is investment in research to develop new treatments the best approach to controlling cancer?
UI Cancer Center, Governors State to address cancer disparities in south suburbs
The University of Illinois Cancer Center and Governors State University have received a joint four-year, $1.5 million grant from the National Cancer Institute to help both institutions conduct community-based research to reduce cancer-related health disparities in Chicago's south suburbs.
Leading cancer research organizations to host international cancer immunotherapy conference
The Cancer Research Institute, the Association for Cancer Immunotherapy, the European Academy of Tumor Immunology, and the American Association for Cancer Research will join forces to sponsor the first International Cancer Immunotherapy Conference at the Sheraton New York Times Square Hotel in New York, Sept.

Related Cancer Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Changing The World
What does it take to change the world for the better? This hour, TED speakers explore ideas on activism—what motivates it, why it matters, and how each of us can make a difference. Guests include civil rights activist Ruby Sales, labor leader and civil rights activist Dolores Huerta, author Jeremy Heimans, "craftivist" Sarah Corbett, and designer and futurist Angela Oguntala.
Now Playing: Science for the People

#521 The Curious Life of Krill
Krill may be one of the most abundant forms of life on our planet... but it turns out we don't know that much about them. For a create that underpins a massive ocean ecosystem and lives in our oceans in massive numbers, they're surprisingly difficult to study. We sit down and shine some light on these underappreciated crustaceans with Stephen Nicol, Adjunct Professor at the University of Tasmania, Scientific Advisor to the Association of Responsible Krill Harvesting Companies, and author of the book "The Curious Life of Krill: A Conservation Story from the Bottom of the World".